Eisai Oncology to Present New Research on
Product Portfolio, Pipeline at ASCO Annual
Meeting
Highlights Include New Phase III Data on Eribulin in Locally Recurrent or Metastatic Breast Cancer
May 21, 2010 08:33 AM Eastern Daylight Time
WOODCLIFF LAKE, N.J.--(EON: Enhanced Online News)--Eisai announced today that 15 abstracts highlighting
new study results on metastatic breast cancer, ovarian cancer, non-small cell lung cancer, metastatic brain cancer,
peripheral T-cell lymphoma and other cancers will be presented during the 46th Annual Meeting of the American
Society of Clinical Oncology (ASCO), taking place in Chicago from June 4 to June 8, 2010. Among the abstracts to
be presented is a Phase III study (EMBRACE) investigating eribulin mesylate versus treatment of physician’s choice
in patients with locally recurrent or metastatic breast cancer who have previously received at least two
chemotherapeutic regimens, including an anthracycline and a taxane.
These studies highlight Eisai’s current product portfolio and oncology pipeline, reinforcing the company’s
commitment to address the diverse needs of patients and their families affected by cancer.
“Oncology is one of Eisai’s longstanding therapeutic areas of focus,” said Takashi Owa, Ph.D., President, Oncology
Product Creation Unit, Eisai Product Creation Systems, Eisai Inc. “The 15 accepted studies show the diversity of
our oncology research. This work underscores our global commitment to discover, develop and produce
progressive oncology therapies that are representative of our human health care mission to address unmet medical
needs and increase benefits to patients and their families.”
The following Eisai abstracts are accepted for presentation at this year’s ASCO meeting:
Eribulin mesylate
A Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician’s Choice in
Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline
and a Taxane
Oral Session
Abstract No: CRA100